Physicians’ Education Resource® Hosts the 38th Annual Miami Breast Cancer Conference® in Expanded, Interactive Virtual Meeting Format
24.2.2021 21:12:00 EET | Business Wire | Press release
As the leading go-to resource for continuing medical education (CME), Physicians’ Education Resource®, LLC, (PER®), has been committed to improving the care for patients with breast cancer by educating the treatment team for nearly four decades. This commitment is more than professional, but also deeply personal. This annual marquee CME conference has been family-led since the beginning and continues to incorporate that family spirit into 2021 in the virtual setting.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005893/en/
Traditionally hosted as a live marquee meeting, this year’s 38th Annual Miami Breast Cancer Conference® has transformed into a live-broadcast virtual and interactive experience leveraging new online meeting technologies. This year, the conference is more than Miami, and will bring the educational experience directly to health care professionals online.
For 37 years, the historic multidisciplinary Miami Breast Cancer Conference® has been a family-led annual meeting. By combining the conference’s legacy with the Hennessy family spirit and commitment infused into the DNA of MJH Life Sciences™, the parent company of PER®, this year’s meeting will continue to focus on improving the care of patients with breast cancer. The annual conference has become a landmark meeting that serves as the go-to resource for health care professionals to learn about the most important advancements in breast cancer treatment and how to translate these into clinical care.
“In its 38th year, whether this is your first time or your 31st time attending, PER® welcomes you as part of the Miami Breast Cancer Conference® family,” said Phil Talamo, CHCP, president of PER®. “Our community is full of dedicated oncologists, surgeons, pathologists, nurses, and more who are committed to elevating patient care. We know that it takes more than a team to treat breast cancer – it takes a family. During this year’s conference, we will virtually come together with a shared purpose of driving contemporary patient care using strategies that you hear on Friday and use on Monday.”
This year’s 38th Annual Miami Breast Cancer Conference® will continue this tradition increase the use innovative virtual technology to deliver the robust educational programming and top-notch presentations for which this conference is known for. New in 2021, PER® has expanded its afternoon programming to the full healthcare team with additional tracks on pathology, radiation oncology, and oncology nursing. To accommodate its international learners in European time zones, an international track will also be offered. This will broaden the Conference’s impact and bring vital members of the treatment team into the Miami Breast Cancer Conference family, united in the approach to improve the care of patients with breast cancer.
Additionally, this year’s expanded virtual program will feature world-class tumor board panels, multidisciplinary meet-the-expert sessions, case discussions, poster sessions, a video surgical library, lively Medical Crossfire® exchanges, and more. Included among the many important clinical and practical topics on the agenda are novel therapeutic targets, contemporary management issues, oncology care in the COVID-19 era, practical application of genomics, precision medicine, and more.
For more information and to register, click here.
About Physicians’ Education Resource® (PER®)
Since 1995, PER® has been dedicated to advancing cancer care through professional education and now advances patient care and treatment strategies on a wide variety of chronic illnesses and diseases. In 2016, PER® initiated continuing medical education (CME) programming in the cardiovascular and endocrinology areas. Although it is expanding into topics outside of oncology, PER® stands as the leading provider of live, online and print CME activities related to oncology and hematology. The high-quality, evidence-based activities feature leading distinguished experts who focus on the application of practice-changing advances. PER® is accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER® is a brand of MJH Life Sciences™, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005893/en/
Contact information
PER® Media
Contact
Alexandra Ventura, 609-716-7777
aventura@mjhlifesciences.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 10:00:00 EEST | Press release
Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defies convention and empowers individuals to express their identity and bring out confidence. At the heart of this vision is the brand’s signature shadow enhancing makeup approach
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom